AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$15.23
-0.24 (-1.55%)
Open$15.48
Previous Close$15.47
Day High$15.49
Day Low$15.12
52W High$24.27
52W Low$10.70
Volume—
Avg Volume1.31M
Market Cap818.39M
P/E Ratio—
EPS$-4.75
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+116.1% upside
Current
$15.23
$15.23
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 236.4K | 1.59M | 36.29M |
| Net Income | -313,708,629 | -1,902,545,593 | 8.09M |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% |
| EBITDA | -290,951,588 | -1,862,560,704 | 9.50M |
| Free Cash Flow | — | — | 4.67M |
| Rev Growth | -85.2% | -85.2% | +16.8% |
| Debt/Equity | 0.03 | 0.03 | 0.47 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |